DRW Securities’s Ligand Pharmaceuticals LGND Stock Holding History

DRW Securities’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2,108	Closed	-$373K	–	1487
2025 Q3	$373K	Buy	+2,108	New	+$313K	0.01%	742

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

DRW Securities's LGND Position: Q4 2025 in Review

DRW Securities sold out of Ligand Pharmaceuticals (LGND) in Q4 2025, closing a stake of 2,108 shares — an estimated $373K sold.

DRW Securities first reported a position in LGND in Q3 2025 and held it in 1 quarter. The position peaked at $373K in Q3 2025. 350 funds tracked by Wall St. Rank hold LGND as of Q4 2025.

DRW Securities reported no remaining Ligand Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
DRW Securities sold 2,108 Ligand Pharmaceuticals shares in Q4 2025, an estimated $373K.
DRW Securities first reported a position in Ligand Pharmaceuticals in Q3 2025 and held it in 1 quarter.
DRW Securities's Ligand Pharmaceuticals position peaked at $373K in Q3 2025.
350 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2025.

Based on DRW Securities's 13F filing for Q4 2025, filed 12 Feb 2026.